Literature DB >> 19070452

A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

Daniel J Diekema1, Shawn A Messer, Richard J Hollis, Linda Boyken, Shailesh Tendolkar, Jennifer Kroeger, Ronald N Jones, Michael A Pfaller.   

Abstract

Voriconazole susceptibility testing was performed on 7191 Candida spp. from 78 centers worldwide between 2004 and 2007. Voriconazole was very active in vitro (MIC(50)/MIC(90), 0.008/0.25 microg/mL; 98% susceptible). In comparison to 5866 Candida spp. isolates collected during global surveillance from 1997 to 2001, there were no changes in voriconazole mean MIC or MIC distribution.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19070452     DOI： 10.1016/j.diagmicrobio.2008.11.001

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  7 in total

1.  Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates.

Authors:  Ronald N Jones; Mariana Castanheira; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

2.  Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.

Authors:  M A Pfaller; A Espinel-Ingroff; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-01-12       Impact factor: 5.948

3.  Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).

Authors:  Michael A Pfaller; Gary J Moet; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

4.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; D Ellis; V Tullio; A Rodloff; W Fu; T A Ling
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

5.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Authors:  M A Pfaller; S A Messer; R J Hollis; L Boyken; S Tendolkar; J Kroeger; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

Review 6.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

7.  Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China.

Authors:  Chun-fang Ma; Fang-qiu Li; Li-ning Shi; Yu-an Hu; Ying Wang; Mei Huang; Qian-qian Kong
Journal:  BMC Infect Dis       Date:  2013-07-22       Impact factor: 3.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.